Dr. Nancy T. Chang - 21 Nov 2025 Form 4 Insider Report for Immix Biopharma, Inc. (IMMX)

Role: Director
Signature: /s/ Dr. Nancy T. Chang
Issuer symbol: IMMX
Transactions as of: 21 Nov 2025
Net transactions value: $0
Form type: 4
Filing time: 11 Dec 2025, 20:00:32 UTC
Previous filing: 17 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
CHANG NANCY T	Director	C/O IMMIX BIOPHARMA, INC., 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES	/s/ Dr. Nancy T. Chang	11 Dec 2025	0001135041

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	IMMX	Common Stock						421,940	21 Nov 2025	Direct
holding	IMMX	Common Stock						496,940	21 Nov 2025	Held by Robinhood II, LP	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMMX	Stock Option (Right to Buy)	Award	$0	+39,643		$0.000000	39,643	21 Nov 2025	Common Stock	39,643	$4.33	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Dr. Nancy T. Chang is the general manager of Robinhood II, LP and may be deemed to beneficially own the securities held by Robinhood II, LP. Dr. Chang disclaims beneficial ownership of the common stock owned directly by Robinhood II, LP, except to the extent of her pecuniary interest therein.
F2	The Stock Option will vest in thirty-six (36) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer and the terms of a Stock Option Agreement entered into to evidence the award.